OrbiMed’s 4D Molecular Therapeutics FDMT Stock Holding History

OrbiMed’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-125,000	Closed	-$5.18M	–	169
2020 Q4	$5.18M	Buy	+125,000	New	+$5.16M	0.05%	139

Other funds holding FDMT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

OrbiMed's FDMT Position: Q1 2021 in Review

OrbiMed sold out of 4D Molecular Therapeutics (FDMT) in Q1 2021, closing a stake of 125,000 shares — an estimated $5.18M sold.

OrbiMed first reported a position in FDMT in Q4 2020 and held it in 1 quarter. The position peaked at $5.18M in Q4 2020. 64 funds tracked by Wall St. Rank hold FDMT as of Q1 2021.

OrbiMed reported no remaining 4D Molecular Therapeutics position as of Q1 2021 after selling out during the quarter.
OrbiMed sold 125,000 4D Molecular Therapeutics shares in Q1 2021, an estimated $5.18M.
OrbiMed first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 1 quarter.
OrbiMed's 4D Molecular Therapeutics position peaked at $5.18M in Q4 2020.
64 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2021.

Based on OrbiMed's 13F filing for Q1 2021, filed 17 May 2021.